Pancreatic AdenocarcinomaNCT07619391
MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer
A study testing Electronic Health Record Review, Smartphone Application-based Intervention and Survey Administration in people with Pancreatic Adenocarcinoma, run by Ohio State University Comprehensive Cancer Center at 1 site in United States.
Trial summary
This clinical trial tests the feasibility of using the MyCap mobile application (app) for tracking time burden from treatment for patients with pancreatic cancer. Pancreatic cancer is best treated with many care teams, such as medical oncology and surgery, requiring patients to dedicate significant time coordinating… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Adenocarcinoma
- What is being tested?
- Electronic Health Record Review, Smartphone Application-based Intervention and Survey Administration
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- 10 Mar 2026to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults ≥ 18 years old
- Diagnosed with pancreatic adenocarcinoma undergoing active treatment or planning to start active treatment within the next 30 days
- English speaking
- Access to a smartphone (Android or iOS)
Who cannot join
- Prisoners
- Patients undergoing cancer surveillance
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
The Ohio State University Comprehensive Cancer Center contact
United States1 site, 1 recruiting
- Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Pamela W. Lu, MD, 614-293-7171, Pamela.lu@osumc.edu
Pamela W. Lu, MD
About this study
Official title: A Mobile App for Tracking Time Burden of Pancreatic Cancer Treatment: A Single-Arm Feasibility Study
This clinical trial tests the feasibility of using the MyCap mobile application (app) for tracking time burden from treatment for patients with pancreatic cancer. Pancreatic cancer is best treated with many care teams, such as medical oncology and surgery, requiring patients to dedicate significant time coordinating appointments among different doctors. This time commitment is referred to as time toxicity, defined as the time spent undergoing cancer-related medical care, such as emergency visits, ambulatory care, lab and infusion visits, hospitalizations, and the commuting and waiting times associated with each. At present, time toxicity is still understudied within the medical literature, with no gold standard established for the method of measurement. The MyCap mobile app may be a feasible way to track the time burden from treatment for patients with pancreatic cancer.
Read the detailed description
PRIMARY OBJECTIVE:
- To assess the feasibility of utilizing a mobile application for patients to self-track the time burden associated with undergoing pancreatic cancer treatment.
OUTLINE:
Patients download the MyCap app onto their phone and fill out a daily time log in the app for 8 weeks.
- Conditions
- Pancreatic Adenocarcinoma
- Being tested
- Electronic Health Record Review, Smartphone Application-based Intervention, Survey Administration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Electronic Health Record ReviewOther
Ancillary studies
Smartphone Application-based InterventionBehavioural
Also called Smartphone App-based Intervention, Smartphone Intervention, Smartphone-based Intervention
Receive access to MyCap application
Survey AdministrationOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Health Services Research (MyCap app) | Experimental | Patients download the MyCap app onto their phone and fill out a daily time log in the app for 8 weeks. Receives: Other: Electronic Health Record Review; Behavioral: Smartphone Application-based Intervention; Other: Survey Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Retention rate (feasibility)
Defined as the number of participants who enroll in the study and complete at least one time log during the study period.
Measured: Up to 8 weeks
Adherence rate (feasibility)
Adherence is defined as the percentage of patients who completed over 80% of time logs. Given that this study is evaluating a daily time log over 8 weeks, adherence would require participants to fill out at least 44-time logs.
Measured: Up to 8 weeks
System usability survey (feasibility)
Measured: Up to 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jun 2026
- Study start10 Mar 2026
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic AdenocarcinomaStudies of the same condition, open and under way.
- More trials run by Ohio State University Comprehensive Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Pamela Lu, Ohio State University Comprehensive Cancer Center
- Investigators
- Pamela W Lu, MD, Principal investigator, Ohio State University Comprehensive Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07619391
- Sponsor's protocol ID
- OSU-23326
- Other IDs
- NCI-2026-03436, 2020C0221
- Status last verified
- May 2026
- First submitted
- 26 May 2026
- Last updated
- 2 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Mobile App for Tracking Time Burden of Pancreatic Cancer Treatment: A Single-Arm Feasibility Study
- ClinicalTrials.gov ID
- NCT07619391
- Acronym / sponsor ID
- OSU-23326
- Conditions
- Pancreatic Adenocarcinoma
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Ohio State University Comprehensive Cancer CenterUniversity, hospital or other
- Study start
- 10 Mar 2026 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 2 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial tests the feasibility of using the MyCap mobile application (app) for tracking time burden from treatment for patients with pancreatic cancer. Pancreatic cancer is best treated with many care teams, such as medical oncology and surgery, requiring patients to dedicate significant time coordinating appointments among different doctors. This time commitment is referred to as time toxicity, defined as the time spent undergoing cancer-related medical care, such as emergency visits, ambulatory care, lab and infusion visits, hospitalizations, and the commuting and waiting times associated with each. At present, time toxicity is still understudied within the medical literature, with no gold standard established for the method of measurement. The MyCap mobile app may be a feasible way to track the time burden from treatment for patients with pancreatic cancer.
Detailed description
PRIMARY OBJECTIVE:
- To assess the feasibility of utilizing a mobile application for patients to self-track the time burden associated with undergoing pancreatic cancer treatment.
OUTLINE:
Patients download the MyCap app onto their phone and fill out a daily time log in the app for 8 weeks.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Health Services Research (MyCap app) | Experimental | Other: Electronic Health Record Review, Behavioral: Smartphone Application-based Intervention, Other: Survey AdministrationPatients download the MyCap app onto their phone and fill out a daily time log in the app for 8 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults ≥ 18 years old
- Diagnosed with pancreatic adenocarcinoma undergoing active treatment or planning to start active treatment within the next 30 days
- English speaking
- Access to a smartphone (Android or iOS)
Key exclusion criteria (2 listed)
- Prisoners
- Patients undergoing cancer surveillance
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Electronic Health Record ReviewAncillary studies | Other | Health Services Research (MyCap app) |
| Smartphone Application-based InterventionAlso: Smartphone App-based Intervention, Smartphone Intervention, Smartphone-based InterventionReceive access to MyCap application | Behavioural | Health Services Research (MyCap app) |
| Survey AdministrationAncillary studies | Other | Health Services Research (MyCap app) |
Primary outcome
Retention rate (feasibility)
Time frame: Up to 8 weeks
Defined as the number of participants who enroll in the study and complete at least one time log during the study period.
Adherence rate (feasibility)
Time frame: Up to 8 weeks
Adherence is defined as the percentage of patients who completed over 80% of time logs. Given that this study is evaluating a daily time log over 8 weeks, adherence would require participants to fill out at least 44-time logs.
System usability survey (feasibility)
Time frame: Up to 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2026.
- The JameslineLink provided by the sponsor.
Related trials for Pancreatic Adenocarcinoma
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Pancreatic Cancer, Pancreatic Cancer Metastatic
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The Ohio State University Comprehensive Cancer Center contact
Pamela W Lu, MD principal investigator
Ohio State University Comprehensive Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Electronic Health Record Review, Smartphone Application-based Intervention and Survey Administration in people with Pancreatic Adenocarcinoma, run by Ohio State University Comprehensive Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact The Ohio State University Comprehensive Cancer Center (800-293-5066, OSUCCCClinicaltrials@osumc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Retention rate (feasibility) (time frame: Up to 8 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.